Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    CBRNE

    Medical Countermeasures for Acute Radiation Syndrome

    By Global Biodefense StaffAugust 17, 2012
    Share
    Facebook LinkedIn Reddit Email

    The National Institute of Allergy and Infectious Diseases (NIAID) has issued a Broad Agency Announcement (BAA) soliciting proposals for development of products for treatment of radiation exposures resulting from nuclear and radiological attacks.

    The BAA seeks organizations with the capabilities to advance the development of candidate medical countermeasures (MCMs) for gastrointestinal acute radiation syndrome (GI-ARS). For this funding activity, it is anticipated that candidate MCMs will enter the evaluation and development pathway at various stages, from early research to post marketing (for drugs or biologics that are already licensed or approved for other indications). Offerors are expected to provide a Statement of Work based on the stage of the candidate and the work that needs to be performed to advance the MCM.

    NIAID’s overall goal is development of products for treatment of radiation exposures resulting from nuclear and radiological attacks to the stage where products are eligible for advanced product development by the Biomedical Advanced Research and Development Authority or acquisition under the Project BioShield Act of 2004.

    It is anticipated that 2-4 contracts will be awarded for a 3-year period of performance beginning on or about July 15, 2013. NIAID estimates that the average annual total cost will be $1-2 million per contract award per year depending on the length and scope of the project. Further details are available under Solicitation Number: BAA-NIAID-DAIT-NIHAI2012147. The current proposal deadline is November 15, 2012.

    Update: The response deadline has been extended to November 29, 2012 due to Superstorm Sandy.

    BAA Radiation
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBiodefense BAA Supports Adjuvant Development for Emerging Diseases
    Next Article BioWatch: Public Health Officials Respond to Criticisms

    Related Stories

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.